Zhejiang Medicine Co., Ltd. (SHA: 600216)
China
· Delayed Price · Currency is CNY 17.70
-0.19 (-1.06%)
Nov 13, 2024, 3:00 PM CST
Zhejiang Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 8,998 | 7,762 | 8,073 | 9,088 | 7,294 | 7,023 | Upgrade
|
| Other Revenue | 32.11 | 32.11 | 43.23 | 41.3 | 32.53 | 20.59 | Upgrade
|
| Revenue | 9,030 | 7,794 | 8,116 | 9,129 | 7,327 | 7,044 | Upgrade
|
| Revenue Growth (YoY) | 14.77% | -3.96% | -11.10% | 24.60% | 4.02% | 2.70% | Upgrade
|
| Cost of Revenue | 5,753 | 5,392 | 5,438 | 5,530 | 4,410 | 4,271 | Upgrade
|
| Gross Profit | 3,278 | 2,402 | 2,678 | 3,599 | 2,917 | 2,772 | Upgrade
|
| Selling, General & Admin | 1,645 | 1,481 | 1,312 | 1,546 | 1,537 | 1,971 | Upgrade
|
| Research & Development | 799.87 | 860.07 | 809.28 | 806.86 | 546.09 | 450.42 | Upgrade
|
| Other Operating Expenses | 86.52 | 78.43 | 69.86 | 75.17 | 73.04 | 69.95 | Upgrade
|
| Operating Expenses | 2,549 | 2,420 | 2,188 | 2,439 | 2,140 | 2,504 | Upgrade
|
| Operating Income | 729.03 | -18.15 | 489.74 | 1,160 | 777.42 | 268.47 | Upgrade
|
| Interest Expense | -28.51 | -28.34 | -33.11 | -39.54 | -46.27 | -25.71 | Upgrade
|
| Interest & Investment Income | 19.36 | 16.51 | 13.18 | 57.42 | 139.56 | 45.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 36.59 | 36.59 | 66.6 | -64.31 | -38.46 | 19.93 | Upgrade
|
| Other Non Operating Income (Expenses) | -7.07 | 21.09 | -36.73 | -2.69 | -31.87 | -9.39 | Upgrade
|
| EBT Excluding Unusual Items | 749.4 | 27.7 | 499.67 | 1,111 | 800.38 | 298.35 | Upgrade
|
| Impairment of Goodwill | -9.23 | -9.23 | -8.12 | - | - | -5.06 | Upgrade
|
| Gain (Loss) on Sale of Investments | -43.07 | -28.59 | -56.51 | 51.73 | 30.48 | 66.9 | Upgrade
|
| Gain (Loss) on Sale of Assets | 315.77 | 323.57 | -1.37 | -7.95 | -23.48 | -2.07 | Upgrade
|
| Asset Writedown | -36.99 | - | - | -46.19 | -9.85 | -4.92 | Upgrade
|
| Other Unusual Items | 49.82 | 49.82 | 57.71 | 44.76 | 53.45 | 44.29 | Upgrade
|
| Pretax Income | 1,026 | 363.28 | 491.39 | 1,154 | 850.98 | 397.5 | Upgrade
|
| Income Tax Expense | 171.21 | 86.48 | 128.77 | 268.97 | 191.34 | 105.54 | Upgrade
|
| Earnings From Continuing Operations | 854.49 | 276.79 | 362.61 | 884.56 | 659.64 | 291.95 | Upgrade
|
| Minority Interest in Earnings | 123.47 | 152.85 | 176.96 | 160.76 | 57.76 | 50.82 | Upgrade
|
| Net Income | 977.95 | 429.64 | 539.57 | 1,045 | 717.4 | 342.77 | Upgrade
|
| Net Income to Common | 977.95 | 429.64 | 539.57 | 1,045 | 717.4 | 342.77 | Upgrade
|
| Net Income Growth | 174.36% | -20.37% | -48.38% | 45.71% | 109.29% | -5.97% | Upgrade
|
| Shares Outstanding (Basic) | 956 | 961 | 964 | 959 | 957 | 952 | Upgrade
|
| Shares Outstanding (Diluted) | 956 | 961 | 964 | 959 | 957 | 952 | Upgrade
|
| Shares Change (YoY) | -2.50% | -0.31% | 0.47% | 0.26% | 0.46% | -0.75% | Upgrade
|
| EPS (Basic) | 1.02 | 0.45 | 0.56 | 1.09 | 0.75 | 0.36 | Upgrade
|
| EPS (Diluted) | 1.02 | 0.45 | 0.56 | 1.09 | 0.75 | 0.36 | Upgrade
|
| EPS Growth | 181.39% | -20.13% | -48.62% | 45.33% | 108.33% | -5.26% | Upgrade
|
| Free Cash Flow | 282.96 | -162.56 | -455.39 | 197.05 | 721.37 | -126.38 | Upgrade
|
| Free Cash Flow Per Share | 0.30 | -0.17 | -0.47 | 0.21 | 0.75 | -0.13 | Upgrade
|
| Dividend Per Share | 0.150 | 0.150 | 0.170 | 0.330 | 0.230 | 1.000 | Upgrade
|
| Dividend Growth | -11.76% | -11.76% | -48.48% | 43.48% | -77.00% | 566.67% | Upgrade
|
| Gross Margin | 36.30% | 30.82% | 33.00% | 39.43% | 39.81% | 39.36% | Upgrade
|
| Operating Margin | 8.07% | -0.23% | 6.03% | 12.71% | 10.61% | 3.81% | Upgrade
|
| Profit Margin | 10.83% | 5.51% | 6.65% | 11.45% | 9.79% | 4.87% | Upgrade
|
| Free Cash Flow Margin | 3.13% | -2.09% | -5.61% | 2.16% | 9.85% | -1.79% | Upgrade
|
| EBITDA | 1,371 | 640.44 | 1,171 | 1,747 | 1,281 | 756.2 | Upgrade
|
| EBITDA Margin | 15.18% | 8.22% | 14.42% | 19.14% | 17.49% | 10.74% | Upgrade
|
| D&A For EBITDA | 641.92 | 658.59 | 680.81 | 586.79 | 503.81 | 487.74 | Upgrade
|
| EBIT | 729.03 | -18.15 | 489.74 | 1,160 | 777.42 | 268.47 | Upgrade
|
| EBIT Margin | 8.07% | -0.23% | 6.03% | 12.71% | 10.61% | 3.81% | Upgrade
|
| Effective Tax Rate | 16.69% | 23.81% | 26.21% | 23.32% | 22.48% | 26.55% | Upgrade
|
| Revenue as Reported | 9,030 | 7,794 | 8,116 | 9,129 | 7,327 | 7,044 | Upgrade
|
| Advertising Expenses | - | 21.25 | 19.59 | 21.3 | 20.8 | 29.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.